Periostin as a predictor of uncontrolled asthma and lung function decrease in patient of different age groups

Introduction. Uncontrolled bronchial asthma (BA) increases risk of hospitalizations, future exacerbations and decreases quality of life; factors improving the probability to achieve BA control are under study.

Methods and materials. The open prospective study included 104 patients of three groups: children (6—11 years, n=38), adolescents (14—17 years, n = 35) and adults (25 — 50 years, n = 31). Inclusion criteria: BA duration >12 month, uncontrolled asthma, absence of acute respiratory infection for 14 days. Clinical history, respiratory function and sampling (serum and nasal brushings) for periostin assay were performed on Visit 1. Maintenance therapy correction and triggers avoiding recommendations were made. Two further visits 6 months apart were done. Statistical processing included ANOVA (Kruskall — Wallis test) and Pearson correlation test. Differences were considered significant when p<0.05.

Results. 75 % of «Children» group,70.6 % of «Adolescents» and 53.6 % of «Adults» had achieved BA control. Obesity, non-atopic phenotype, FEV1 <65 % of predicted were risk factors of uncontrolled BA. Serum periostin levels were highest in uncontrolled BA subgroup, Me [Q25; Q75] =32.9 [28.6; 39.1] ng/ml. Nasal periostin levels were highest in «Adolescent» group: 9.8 [4.8; 11.2] ng/ml. Nasal periostin and low FEV1 had moderate reverse correlation (r=—0.61).

Conclusion. Serum and nasal periostin levels could indicate treatment efficacy and prognose future risks of BA control loss.

1. Federal clinical recommendations on bronchial asthma. Moscow, RRS, 2019:97. (In Russ.).

2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2020 update). Available at: www.ginasthma.org (accessed: 30.08.2020).

3. Castro-Rodriguez J. A, Saglani S., Rodriguez-Martinez C. E, Oyarzun M. A, Fleming L., Bush A. The relationship between inflammation and remodeling in childhood asthma: A systematic review // Pediatr Pulmonol. 2018;53(6):824-835. Doi: 10.1002/ppul.23968.

4. Papi A., Brightling C., Pedersen S. E., Reddel H. K. Asthma // Lancet. 2018;391(10122):783-800. Doi: 10.1016/S0140-6736(17)33311-1

5. Papadopoulos N. G, Arakawa H., Carlsen K. H, Custovic A., Gern J., Lemanske R. International consensus on (ICON) pediatric asthma // Allergy. 2012;(67):976-997. Doi: 10.1111/j.1398-9995.2012.02865.x.

6. Ray A., Camiolo M., Fitzpatrick A., Gauthier M., Wenzel S. E. Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma? // Physiol Rev. 2020;100(3): 9831017. Doi: 10.1152/physrev.00023.2019.

7. Edited by Fedoseev G. B., Trofimov V. I., Petrova M. A. Multiple faces of bronchial asthma: diagnostics, treatment and prevention. SPb., Nordmedizdat, 2011:343. (In Russ.).

8. Natsional'naya programma «Bronkhial'naya astma u detei. Strategiya lecheniya i profilaktika». 5-e izd., pererab. i dop. Moscow, Original-maket, 2017:160. (In Russ.).

9. Kamaev A. V., Makarova I. V., Trusova O. V. Kriterii otbora pediatricheskix pacientov dlya bazisnoj terapii omalizumabom kak glavny'j faktor dolgosrochnogo podderzhaniya kontrolya tyazheloj bronxial'noj astmy' // Pediatriya. Zhurnal im. G. N. Speranskogo. 2018;97(2):61-67. (In Russ.).

10. Rabe K. F., Adachi M., Lai C. K., Soriano J. .B, Vermeire P. A., Weiss K. B., Weiss S. T. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys // J. Allergy Clin Immunol. 2004;114(1):40-47.

11. Kamaev A. V., Makarova I. V., Pashhenko N. A., Trusova O. V, Korostovcev D. S. Kontrol' nad tyazhely'm techeniem bronxial'noj astmy' u detej: izmeneniya za poslednie 5 let // Pediatr. 2010;1(1):49-53. (In Russ.).

12. Hekking P. P., Wener R. R., Amelink M., Zwinderman A. H., Bouvy M. L., Bel, E. H. The prevalence of severe refractory asthma // The Journal of allergy and clinical immunology/ 2015;135(4):896-902. Doi: 10.1016/j.jaci.2014.08.042.

13. Arron J. R., Izuhara K. Asthma biomarkers: what constitutes a «gold standard» // Thorax. 2015;70(2):105-107. Doi: 10.1136/thoraxjnl-2014-206069.

14. Izuhara K., Nunomura S., Nanri Y., Ono J., Takai M., Kawaguchi A. Periostin: an emerging biomarker for allergic diseases // Allergy. 2019;(74):2116e28.

15. Noguchi T., Nakagome K., Kobayashi T., Uchida Y., Soma T., Nakamoto H., et al. Periostin upregulates the effector functions of eosinophils // J Allergy Clin Immunol. 2016; (138):1449-14452.

16. Matsumoto H. Role of serum periostin in the management of asthma and its comorbidities // Respiratory Investigation. Doi: 10.1016/j.resinv.2020.02.003.

17. Bousquet J., Hellings P. W., Agache I., Bedbrook A., Bachert C., Bergmann K. C. et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle // Clin Transl Allergy. 2016;30(6):47. Doi: 10.1186/s13601-016-0137-4.

18. Holgate S. T., Wenzel S., Postma D. S., Weiss S. T., Renz H., Sly P. D. Asthma // Nat Rev Dis Primers. 2015; 1(1):15025. Doi: 10.1038/nrdp.2015.25.

19. Quanjer P. H., Brazzale D. J., Boros P. W., Pretto J. J. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry // Eur. Respir. J. 2013;42(4):1046-1054. Doi: 10.1183/09031936.00195512.

20. RADAR. Allergicheskij rinit u detej : rekomendacii i algoritm pri detskom allergicheskom rinite. Moscow, Original-maket, 2015:80. (In Russ.).

21. Chipps B. E., Haselkorn T., Paknis B., Ortiz B., Bleecker E. R., Kianifard, F., et al. More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II // Journal of Allergy and Clinical Immunology. 2018;141(5):1590-1597.e9. Doi: 10.1016/j.jaci.2017.07.014 .

22. Bitsko M. J., Everhart R. S., Rubin B. C. The Adolescent with Asthma // Paediatr. Respir. Rev. 2013. Doi: 10.1016/j.prrv.2013.07.003

23. Burgess J. K., Jonker M. R., Berg M., Ten Hacken N. T. H., Meyer K. B., van den Berge M., Nawijn M. C., Heijink I. H. Periostin: contributor to abnormal airway epithelial function in asthma? // Eur Respir J. 2020:2001286. Doi: 10.1183/13993003.01286-2020. Epub ahead of print. PMID: 32907887.

24. Stokes A. B., Kieninger E., Schogler A., Kopf B. S., Casaulta C., Geiser T., Regamey N., Alves M. P. Comparison of three different brushing techniques to isolate and culture primary nasal epithelial cells from human subjects // Experimental lung research. 2014;40(7):327-332. Doi: 10.3109/01902148.2014.925987

25. Raulf-Heimsoth M., Wirtz C., Papenfuss F., Baur X. Nasal lavage mediator profile and cellular composition of nasal brushing material during latex challenge tests // Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2000;30(1):110-121. Doi: 10.1046/j.1365-2222.2000.00690.x

26. Nejman-Gryz P., Gorska K., Paplinska-Goryca M., Proboszcz M., Krenke R. Periostin and Thymic Stromal Lymphopoietin - Potential Crosstalk in Obstructive Airway Diseases // Journal of clinical medicine, 2020;9(11):3667. Doi: 10.3390/jcm9113667.

27. James A., Janson C., Malinovschi A., Holweg C., Alving K., Ono J. et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population based cohort Swedish GA(2)LEN // Allergy. 2017; (72):1753e60.